Lithium levels in human and mouse brains influence Alzheimer’s disease effects, but targeted replacement therapy may hold the key to intervention.



Summary

Studies show that lithium, a mood-stabilizing drug, impacts Alzheimer’s disease (AD) pathology in both human and mouse brains. Natural lithium levels in the brain appear to have a protective effect, with lower levels potentially exacerbating AD symptoms like amyloid plaque formation and cognitive decline. However, the critical insight is that targeted lithium replacement, rather than simply increasing overall lithium intake, might be the key to therapeutic intervention. This approach focuses on restoring optimal lithium levels in specific brain regions affected by AD, holding promise for future AD treatments.

Read more…

This post is part of “Science and Technology News”, Follow for more…!!!

Credits: Source

Disclaimer